Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-08-15 4:03 pm Purchase | 13G | Elevation Oncology Inc. ELEV | GREAT POINT PARTNERS LLC | 3,877,172 6.56% | 3,877,172 (New Position) | View |
| 2024-08-08 9:05 pm Sale | 13D | Elevation Oncology Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,031,920 3.4% | -505,851 (-19.93%) | View |
| 2024-07-15 1:17 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Frazier Life Sciences Public Fund L.P. | 5,993,579 11% | 3,035,000 (+102.58%) | View |
| 2024-04-09 4:26 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Frazier Life Sciences Public Fund L.P. | 2,958,579 6.1% | 2,958,579 (New Position) | View |
| 2024-02-14 6:42 pm Purchase | 13G | Elevation Oncology Inc. ELEV | ORBIMED ADVISORS LLC | 3,000,000 6.8% | 3,000,000 (New Position) | View |
| 2024-02-14 4:45 pm Purchase | 13G | Elevation Oncology Inc. ELEV | K2 HealthVentures Equity Trust LLC | 1,784,169 4% | 217,705 (+13.90%) | View |
| 2024-02-14 4:10 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Point72 Asset Management L.P. | 4,040,000 9.4% | 1,918,830 (+90.46%) | View |
| 2024-02-14 4:00 pm Purchase | 13G | Elevation Oncology Inc. ELEV | TANG CAPITAL PARTNERS LP | 4,300,454 9.99% | 2,944,628 (+217.18%) | View |
| 2024-02-14 3:02 pm Sale | 13G | Elevation Oncology Inc. ELEV | Cormorant Asset Management LP | 0 0% | -1,952,032 (Position Closed) | View |
| 2024-02-14 10:01 am Purchase | 13G | Elevation Oncology Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 4,450,885 9.99% | 2,138,685 (+92.50%) | View |
| 2024-02-07 4:05 pm Sale | 13G | Elevation Oncology Inc. ELEV | ExodusPoint Capital Management LP | 50,000 0.1% | -1,364,824 (-96.47%) | View |
| 2024-02-06 4:15 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Aisling Capital IV LP | 2,878,296 6.8% | 1,735 (+0.06%) | View |
| 2024-01-31 4:32 pm Purchase | 13G | Elevation Oncology Inc. ELEV | INTEGRATED CORE STRATEGIES (US) LLC | 2,990,279 7.1% | 1,592,897 (+113.99%) | View |
| 2024-01-22 4:57 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Logos Global Management LP | 3,650,000 8.6% | 3,650,000 (New Position) | View |
| 2024-01-22 09:02 am Purchase | 13G | Elevation Oncology Inc. ELEV | Farallon Capital Partners L.P. | 3,100,000 7.3% | 3,100,000 (New Position) | View |
| 2024-01-09 4:24 pm Sale | 13G | Elevation Oncology Inc. ELEV | Qiming U.S. Healthcare GP II LLC | 0 0% | -2,370,142 (Position Closed) | View |
| 2024-01-09 09:07 am Purchase | 13G | Elevation Oncology Inc. ELEV | Empery Asset Management LP | 4,000,000 6.7% | 4,000,000 (New Position) | View |
| 2023-06-15 4:30 pm Purchase | 13D | Elevation Oncology Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,537,771 6.1% | 671,432 (+35.98%) | View |
| 2023-06-09 4:15 pm Purchase | 13G | Elevation Oncology Inc. ELEV | ExodusPoint Capital Management LP | 1,414,824 5.8% | 1,414,824 (New Position) | View |
| 2023-06-08 4:30 pm Purchase | 13G | Elevation Oncology Inc. ELEV | INTEGRATED CORE STRATEGIES (US) LLC | 1,397,382 5.7% | 1,397,382 (New Position) | View |